
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type from the provided ranked marker list, I will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **ESR1 (Estrogen Receptor 1):** A nuclear hormone receptor for estrogen, playing a crucial role in the development and progression of breast cancer.<br>- **GATA3:** A transcription factor involved in the regulation of gene expression in mammary gland development and differentiation.<br>- **XBP1:** A transcription factor involved in the unfolded protein response and associated with breast cancer.<br>- **FGF10 (Fibroblast Growth Factor 10):** Involved in cell growth and tissue repair, often associated with epithelial cells.<br>- **CXCL14:** A chemokine involved in immune cell recruitment, often expressed in epithelial tissues.<br>- **TFF1 (Trefoil Factor 1):** Involved in mucosal protection and repair, commonly expressed in breast tissue.<br>- **TFF3 (Trefoil Factor 3):** Similar to TFF1, involved in epithelial cell protection and repair.<br>- **AZGP1 (Zinc-alpha-2-glycoprotein):** Involved in lipid metabolism and often expressed in breast tissue.<br>- **PLAT (Tissue Plasminogen Activator):** Involved in the breakdown of blood clots, expressed in various tissues including breast.<br>- **IFI27, IFI6, ISG15, BST2:** Interferon-stimulated genes, often upregulated in response to viral infections or in certain cancer types.<br><br>### Step 2: List the Key Cell Type Markers<br>- **ESR1, GATA3, TFF1, TFF3, AZGP1:** These markers are highly indicative of luminal epithelial cells in the breast, particularly luminal progenitor or mature luminal cells.<br>- **PIP (Prolactin Induced Protein):** Commonly expressed in breast tissue, associated with luminal epithelial cells.<br>- **AGR2, AGR3:** Associated with secretory epithelial cells, often found in breast tissue.<br>- **SLITRK6, CLEC3A, PRSS23:** These markers are less specific but can be associated with epithelial cell types.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and recent literature on breast cancer scRNA-seq datasets, the markers ESR1, GATA3, TFF1, TFF3, and AZGP1 are consistently associated with luminal epithelial cells in breast tissue.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of key markers such as ESR1, GATA3, TFF1, TFF3, and AZGP1, the most probable general cell type is **luminal epithelial cells** in the breast.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Luminal A Epithelial Cells:** Characterized by high expression of ESR1, GATA3, and TFF1, these cells are hormone receptor-positive and less aggressive.<br>2. **Luminal B Epithelial Cells:** Similar to Luminal A but with a higher proliferation rate and possibly lower expression of ESR1.<br>3. **Luminal Progenitor Cells:** These cells may express some luminal markers but also show markers indicative of a progenitor state, such as AGR2 and AGR3.<br><br>The most likely subtype based on the markers is **Luminal A Epithelial Cells**, given the high expression of ESR1, GATA3, and TFF1.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of luminal epithelial cells. The expression of key markers such as ESR1, GATA3, TFF1, and TFF3 strongly indicates a luminal epithelial cell type, with the most probable subtype being Luminal A Epithelial Cells. These cells are characterized by hormone receptor positivity and are commonly found in breast cancer tissues.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    
                    Validation result: VALIDATION FAILED<br><br>Feedback: <br><br>1. **Marker Consistency:**<br>   - The proposed annotation result identifies key markers such as ESR1, GATA3, TFF1, TFF3, and AZGP1 as indicative of luminal epithelial cells. These markers are indeed present in the provided marker list, which supports the annotation.<br>   - However, the annotation also mentions markers like XBP1 and FGF10, which are not directly associated with luminal epithelial cells in the context of breast tissue. While they are present in the marker list, their role in identifying luminal epithelial cells is less clear and should be reconsidered or justified with additional evidence.<br><br>2. **Mixed Cell Type Consideration:**<br>   - The presence of markers such as IFI27, IFI6, ISG15, and BST2, which are interferon-stimulated genes, suggests a potential mixed cell population or a response to a specific condition (e.g., viral infection or inflammation). These markers are not typically associated with luminal epithelial cells and may indicate the presence of immune cells or other cell types.<br>   - Additionally, markers like SLITRK6, CLEC3A, and PRSS23, which are mentioned as less specific, could suggest the presence of other epithelial or non-epithelial cell types.<br><br>3. **Recommendation for Revision:**<br>   - Re-evaluate the role of markers like XBP1 and FGF10 in the context of luminal epithelial cells and provide additional justification if they are to be included as key markers.<br>   - Investigate the potential presence of mixed cell types, especially considering the expression of interferon-stimulated genes and less specific markers. This may require further analysis or validation using additional datasets or experimental methods.<br>   - Consider providing a more nuanced annotation that accounts for the possibility of mixed cell populations, especially if multiple distinct cell types are supported by high-ranking markers.<br><br>By addressing these points, the annotation can be revised to provide a more accurate and comprehensive characterization of the cell cluster.
                </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To address the validation feedback and provide an updated annotation, I will re-evaluate the marker list and consider the potential presence of mixed cell types. Here is the revised analysis:<br><br>### Step 1: List the Key Functional Markers<br>- **ESR1 (Estrogen Receptor 1):** A key marker for luminal epithelial cells in breast tissue, involved in hormone receptor signaling.<br>- **GATA3:** A transcription factor critical for luminal cell differentiation in the mammary gland.<br>- **TFF1 and TFF3 (Trefoil Factors):** Involved in epithelial cell protection and repair, commonly expressed in breast tissue.<br>- **AZGP1 (Zinc-alpha-2-glycoprotein):** Associated with lipid metabolism and often expressed in breast tissue.<br>- **PIP (Prolactin Induced Protein):** Expressed in breast tissue, associated with luminal epithelial cells.<br>- **AGR2 and AGR3:** Associated with secretory epithelial cells, often found in breast tissue.<br><br>### Step 2: List the Key Cell Type Markers<br>- **ESR1, GATA3, TFF1, TFF3, AZGP1, PIP:** Strongly indicative of luminal epithelial cells in the breast.<br>- **IFI27, IFI6, ISG15, BST2:** Interferon-stimulated genes, suggesting a potential immune response or mixed cell population.<br>- **SLITRK6, CLEC3A, PRSS23:** These markers may indicate other epithelial or non-epithelial cell types.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas and CellMarker, the markers ESR1, GATA3, TFF1, TFF3, and AZGP1 are consistently associated with luminal epithelial cells. However, the presence of interferon-stimulated genes suggests a potential mixed cell population, possibly including immune cells.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>The expression of key markers such as ESR1, GATA3, TFF1, TFF3, and AZGP1 suggests that the primary cell type is **luminal epithelial cells**. However, the presence of interferon-stimulated genes indicates a potential mixed cell population, possibly including immune cells.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Luminal Epithelial Cells:** Characterized by high expression of ESR1, GATA3, TFF1, and TFF3.<br>2. **Immune Cells (e.g., Lymphocytes or Macrophages):** Suggested by the expression of interferon-stimulated genes like IFI27, IFI6, ISG15, and BST2.<br>3. **Other Epithelial Cells:** Indicated by markers like SLITRK6, CLEC3A, and PRSS23, which may represent other epithelial subtypes or non-epithelial cells.<br><br>The most likely primary subtype remains **Luminal Epithelial Cells**, but the presence of immune markers suggests a mixed population.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is primarily composed of luminal epithelial cells, as indicated by markers such as ESR1, GATA3, TFF1, and TFF3. However, the presence of interferon-stimulated genes like IFI27, IFI6, ISG15, and BST2 suggests a potential mixed cell population, possibly including immune cells. This indicates that the dataset may contain a combination of luminal epithelial cells and immune cells, reflecting a complex tissue microenvironment.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The revised annotation has addressed the previous feedback and now provides a more comprehensive analysis of the cell cluster, considering the potential presence of mixed cell types. Here are the key points supporting the validation:<br><br>1. **Marker Consistency:**<br>   - The key markers for luminal epithelial cells, such as ESR1, GATA3, TFF1, TFF3, and AZGP1, are present in the provided marker list and are consistently associated with luminal epithelial cells in breast tissue.<br>   - The inclusion of PIP, AGR2, and AGR3 further supports the identification of luminal epithelial cells and secretory epithelial cells, which are relevant to breast tissue.<br><br>2. **Mixed Cell Type Consideration:**<br>   - The annotation now acknowledges the presence of interferon-stimulated genes (IFI27, IFI6, ISG15, BST2) and suggests the potential presence of immune cells, which is a reasonable consideration given the expression of these markers.<br>   - The mention of markers like SLITRK6, CLEC3A, and PRSS23 as indicative of other epithelial or non-epithelial cell types is appropriate and suggests a nuanced understanding of the potential complexity within the cell cluster.<br><br>3. **Cross-referencing with Databases:**<br>   - The use of databases such as the Human Protein Atlas and CellMarker to support the association of key markers with luminal epithelial cells adds credibility to the annotation.<br><br>4. **Comprehensive Summary:**<br>   - The summary effectively communicates the primary identification of luminal epithelial cells while acknowledging the potential mixed cell population, reflecting a complex tissue microenvironment.<br><br>Overall, the revised annotation provides a balanced and well-supported analysis of the cell cluster, taking into account both the primary cell type and the potential presence of additional cell types. This comprehensive approach aligns with the context provided by the marker list.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Luminal Epithelial Cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Immune Cells</li><li>Other Epithelial Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Luminal Epithelial Cells</li><li>Immune Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">85</div>
                        <div class="scoring-content">
                            The annotation results demonstrate a thorough analysis of the single-cell data, with a strong focus on identifying luminal epithelial cells as the primary cell type. The use of key markers such as ESR1, GATA3, TFF1, TFF3, and AZGP1 is scientifically accurate and aligns well with known literature on breast cancer and luminal epithelial cells. The annotation also appropriately considers the presence of interferon-stimulated genes (IFI27, IFI6, ISG15, BST2), suggesting a potential mixed cell population that includes immune cells. This consideration adds depth to the analysis, acknowledging the complexity of the tissue microenvironment.<br><br>The annotation process shows a balanced approach by not over-focusing on a single marker but rather integrating multiple markers to form a comprehensive view. The inclusion of markers like PIP, AGR2, and AGR3 further supports the identification of luminal epithelial and secretory epithelial cells, which are relevant to breast tissue. The revised annotation effectively addresses previous feedback by considering the potential presence of mixed cell types, which enhances the overall accuracy and comprehensiveness of the analysis.<br><br>However, there are some areas for improvement. The initial mention of markers like XBP1 and FGF10, which are not directly associated with luminal epithelial cells, could have been better justified or omitted in the final analysis. Additionally, while the annotation acknowledges the rank of markers, it could have emphasized the importance of the top-ranked markers more explicitly in the final summary.<br><br>Overall, the annotation provides a well-rounded and scientifically sound analysis of the cell populations, capturing the general picture effectively while considering the complexity of the dataset.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    